Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.,Journal of Diabetes Investigation

当前位置： X-MOL 学术 › J. Diabetes Investig. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Journal of Diabetes Investigation ( IF 3.1 ) Pub Date : 2020-03-25 , DOI: 10.1111/jdi.13237
Baodi Xing ₁ , Yuhang Zhao ₁ , Bingzi Dong ₁ , Yue Zhou ₁ , Wenshan Lv ₁ , Wenjuan Zhao ₁

Affiliation

Non‐alcoholic fatty liver disease (NAFLD) is increasingly common in patients with type 2 diabetes mellitus. Currently, some studies have found that sodium–glucose cotransporter 2 (SGLT2) inhibitors, a new hypoglycemic drug, can improve non‐alcoholic fatty liver in addition to its hypoglycemic effect. Thus, we undertook a meta‐analysis of randomized controlled trials to evaluate the efficacy of SGLT2 inhibitors on the treatment of NAFLD.

中文翻译：

钠-葡萄糖协同转运蛋白 2 抑制剂对 2 型糖尿病患者非酒精性脂肪肝的影响：随机对照试验的荟萃分析。

非酒精性脂肪肝（NAFLD）在 2 型糖尿病患者中越来越常见。目前，一些研究发现钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为一种新型降糖药物，除了具有降血糖作用外，还可以改善非酒精性脂肪肝。因此，我们对随机对照试验进行了荟萃分析，以评估 SGLT2 抑制剂治疗 NAFLD 的疗效。

更新日期：2020-03-25

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11